

March 16, 2017

Dear Rosetta Genomics Ltd. Investor:

On March 16, 2017, Rosetta effected a one-for-twelve reverse stock split.

As a result, Rosetta shareholders will receive one new Rosetta share for every twelve shares that they held prior to the reverse stock split. Further details about the reverse stock split can be found in the FAQs Regarding Reverse Stock Split on March 16, 2017 on the Investors page of our web site: [].

The reverse stock split is intended to increase the per share trading price of Rosetta's ordinary shares to satisfy the \$1.00 minimum bid price requirement for continued listing on the NASDAQ Capital Market.

Thank you for your continued support.

Sincerely,

Kenneth A. Berlin
President and Chief Executive Officer
Rosetta Genomics Ltd.

Forward-Looking Statements

Various statements in this letter constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995, including, without limitation, statements relating to the ability of Rosetta to satisfy the \$1.00 minimum bid price requirement for continued listing on the NASDAQ Capital Market. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed in the "Risk Factors" section of Rosetta's Annual Report on Form 20-F for the year ended December 31, 2015 as filed with the Securities and Exchange Commission. In addition, any forward-looking statements represent Rosetta's views only as of the date of this letter and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.

67775272v.2